Clinical and immunologic predictors of death after an acute opportunistic infection: Results from ACTG A5164

HIV Clinical Trials

Volumn 15, Issue 4, 2014, Pages 133-139

  Grant, Philip ^a   Komarow, Lauren ^b   Sanchez, Alejandro ^c   Sattler, Fred ^c   Asmuth, David ^d   Pollard, Richard ^d   Zolopa, Andrew ^a  

^a STANFORD UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV infections complications; mortality; opportunistic infections

Indexed keywords

ALBUMIN; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ALBUMIN BLOOD LEVEL; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CRYPTOCOCCAL MENINGITIS; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INVASIVE ASPERGILLOSIS; LIVER CIRRHOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SEPSIS;

HIV INFECTIONS/COMPLICATIONS; MORTALITY; OPPORTUNISTIC INFECTIONS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84906684880     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1504-133     Document Type: Article

References (33)

1. Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10(9):e1001510.
2. Harris JE. Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA. 1990;263(3):397-401.
3. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodefi ciency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New Engl J Med. 1997;337(1):15-21.
4. Jabs DA, Gilpin AM, Min YI, Erice A, Kempen JH, Quinn TC. HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial. AIDS (Lond). 2002;16(6):877-887.
5. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fl uid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS (Lond). 2009;23(6):701-706.
6. Varma JK, Nateniyom S, Akksilp S, et al. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: An observational study. BMC Infect Dis. 2009;9:42.
7. Croda J, Croda MG, Neves A, De Sousa dos Santos S. Benefi t of antiretroviral therapy on survival of human immunodefi ciency virus-infected patients admitted to an intensive care unit. Crit Care Med. 2009;37(5):1605- 1611.
8. Ravimohan S, Tamuhla N, Steenhoff AP, et al. Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. J Infect Dis. 2013;208(11):1784-1793.
9. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637-1646.
10. Grant PM, Komarow L, Lederman MM, et al. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution infl ammatory syndrome during ACTG A5164. J Infect Dis. 2012;206(11):1715-1723.
11. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201(12):1796-1805.
12. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PloS One. 2009;4(5):e5575.
13. Armstrong-James D, Copas AJ, Walzer PD, Edwards SG, Miller RF. A prognostic scoring tool for identification of patients at high and low risk of death from HIVassociated Pneumocystis jirovecii pneumonia. Int J STD AIDS. 2011;22(11):628-634.
14. Fanjul F, Riveiro-Barciela M, Gonzalez J, et al. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: Do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score ? HIV Med. 2013;14(5):321-325.
15. Wachter RM, Russi MB, Bloch DA, Hopewell PC, Luce JM. Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis. 1991;143(2):251-256.
16. Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis. 2008;46(4):625-633.
17. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIVassociated Cryptococcal meningitis: Implications for improving outcomes. Clin Infect Dis. 2014;58(5):736-745.
18. Bennett CL, Weinstein RA, Shapiro MF, et al. A rapid preadmission method for predicting inpatient course of disease for patients with HIV-related Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1994; 150(6 Pt 1):1503-1507.
19. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New Engl J Med. 2011;365(16):1471-1481.
20. Levine RS, Briggs NC, Kilbourne BS, et al. Black-White mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health. 2007;97(10):1884-1892.
21. Lemly DC, Shepherd BE, Hulgan T, et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis. 2009;199(7):991-998.
22. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
23. McDonald B, Moyo S, Gabaitiri L, et al. Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: Results from a clinical trial. AIDS Res Human Retroviruses. 2013;29(7):993-999.
24. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780-790.
25. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208(2):249-259.
26. Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution infl ammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Med. 2010;7(12):e1000384.
27. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235-238.
28. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308(4): 379-386.
29. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution infl ammatory syndrome: The trouble with immunity when you had none. Nature Rev Microbiol. 2012;10(2):150-156.
30. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 2006;12(12): 1365-1371.
31. Andrade BB, Hullsiek KH, Boulware DR, et al. Biomarkers of inflammation and coagulation are associated with mortality and hepatitis fl ares in persons coinfected with HIV and hepatitis viruses. J Infect Dis. 2013;207(9): 1379-1388.
32. Benfi eld TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, Lundgren JD. Prognostic value of interleukin-8 in AIDSassociated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1995;151(4):1058-1062.
33. Cozzi-Lepri A, French MA, Baxter J, et al. Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: Results from a large international clinical trial. AIDS (Lond). 2011;25(9):1207-1217.